INTRODUCTION
Carbapenem-resistant
Enterobacteriaceae (CRE) represent a substantial threat to modern health care, challenging our present antibiotic armamentarium and increasing mortality and health care costs, particularly among chronically ill and immunocompromised patients (
1). In the United States,
Klebsiella pneumoniae bacteria, particularly the widespread health care-associated ST258 clone, have accounted for the majority of CRE infections since their initial detection in the early 2000s (
2). However, reports of recent studies from throughout the United States have documented the expanding distribution of carbapenem-resistant
Enterobacter cloacae complex (CREC) (
3–11), while the incidence of carbapenem-resistant
K. pneumoniae resistance has remained stable or has declined in some areas (
7,
10,
12). Overall, the genomic background of CREC is characterized by high clonal diversity (
7,
8). However, accumulating evidence suggests the widespread distribution and epidemic potential of two high-risk CREC clones, ST171 and ST78 (
4–7). In most studies, ST171 and ST78 isolates harbored the plasmid-encoded
K. pneumoniae carbapenemase (KPC), while diverse resistance mechanisms were detected in other clonal backgrounds (
7,
8). Taken together, these data suggest that the emergence of CREC has a complex history, driven in part by its ability to acquire and maintain
blaKPC-harboring plasmids.
Whole-genome sequencing (WGS) has demonstrated the development of CREC clonal outbreaks superimposed on a background of diverse multidrug-resistant (MDR) lineages. A WGS study of MDR
E. cloacae in the United Kingdom and Ireland revealed substantial heterogeneity among patterns of clonal spread and emergence of antibiotic resistance but included very few carbapenem-resistant isolates (
13). WGS analysis of a localized CREC outbreak in Minnesota and North Dakota was consistent with a clonal outbreak of ST171 associated with an IncFIA plasmid harboring
blaKPC-3 (
6). More recently, Chavda et al. explored the phylogenetic structure of geographically diverse carbapenem-resistant and carbapenem-susceptible
Enterobacter spp., demonstrating diverse mechanisms of resistance driven largely by horizontal transfer of
blaKPC-harboring plasmids followed by clonal spread (
8). However, to date, little has been known about the timeline of the recent evolution of CREC and its dominant clones in the context of the introduction of carbapenems in the mid-1980s. Additional gaps in knowledge, including the unique genetic features of ST171 and ST78 and their potential impact on the success of these two high-risk clones, could have important clinical and infection control implications. Here we aimed to elucidate the genomic epidemiology of CREC at a New York City hospital and to investigate the evolutionary relationships between ST171 and ST78 genomes in New York City and geographically diverse locations. Using whole-genome phylogenetic and phylogeographic analyses, we assessed the spatiotemporal spread and distribution of mobile genetic elements (MGEs) within ST171 and ST78 clonal sublineages. We also considered the potential contribution of resistance and virulence determinants to the recent emergence of CREC in the United States and worldwide.
DISCUSSION
In this comprehensive collection of newly sequenced CREC isolates and published genomes, we found evidence for five putative mechanisms of CREC evolution and dissemination (summarized in
Fig. 6). These included (i) independent acquisition of
blaKPC in ST171 by at least two distinct clonal sublineages with subsequent clonal spread and regional outbreaks; (ii) multiple instances of
blaKPC uptake into a dominant ESBL clone, ST78; (iii) distribution of an IncN plasmid among several different STs, indicating a possible hypertransmissible plasmid; (iv) uptake of a variety of carbapenemase gene-harboring plasmids into diverse STs; and (v) sporadic emergence of non-carbapenemase-producing isolates. Overall, the introduction of
blaKPC into multiple
E. cloacae complex clones, including several distinct ST171 and ST78 sublineages, suggests that a combination of species-specific and external factors, such as antibiotic pressure, has contributed to the widespread emergence of CREC.
Our study provided robust evidence for the spread of two distinct ST171 clades across the United States, including a successful blaKPC-3-harboring sublineage demonstrating multiple foci of rapid, regionalized clonal proliferation in the Northeastern and northern Midwestern United States. Within the two clades, we also identified links between isolates from different regional and international locations, highlighting the potential for transmission of high-risk clones to contribute to the global spread of CRE. Although results of in vitro experiments suggested that ST171 is a low-virulence organism relative to other E. cloacae clones, ST171 isolates demonstrated remarkable cross-class resistance to antibiotics used commonly to treat Gram-negative infections, with the exception of amikacin. Notably, the acquisition of carbapenem and fluoroquinolone resistance determinants prior to widespread use of carbapenems and fluoroquinolones suggests that ST171 was already present in hospital settings prior to the mid-1980s and may have proliferated in the setting of rising antibiotic pressure.
Conversely, the emergence of CREC ST78 was characterized by multiple instances of sporadic uptake of
blaKPC-harboring plasmids without evidence of extensive clonal spread. We identified three different CREC subclades defined by different
blaKPC subtypes and a large sublineage of isolates from northern Manhattan demonstrating update of the plasmid-mediated
blaCTX-M-15 ESBL gene. Moreover, ST78 isolates harbored unique genetic factors that may make this clone particularly adept at thriving in nosocomial environments, such as metal-binding and resistance proteins and genes putatively enabling niche-specific colonization. Given that previous population analyses of MDR
E. cloacae demonstrated that ST78 is a widespread, globally dominant ESBL clone (
28,
29), this suggests that ST78 is a highly successful hospital-associated clone with a unique ability to accept plasmids harboring resistance genes.
In addition to high-risk CREC clones, our findings suggest that increased attention to plasmid-mediated transmission of
blaKPC is also warranted. We found evidence for recent horizontal transfer of a hypertransmissible IncN plasmid harboring
blaKPC, which was identified in multiple CREC clones and demonstrated relatively high
in vitro transformation efficiency. Among previous studies, IncN family plasmids were frequently implicated in dissemination of
blaKPC among multiple bacterial strains (
30,
31). Interestingly, pNR0276 was found to be closely related to
blaKPC-harboring IncN plasmids collected in the 1990s (
26), further suggesting that it is a well-established plasmid backbone with the potential to enable multispecies spread of
blaKPC. However, we also detected a wide diversity of CREC isolates harboring heterogeneous plasmids, particularly among
blaKPC-harboring isolates. This may be driven by a growing hospital reservoir of
blaKPC-harboring plasmids as well as intrinsic factors that enable rapid uptake and acquisition of novel plasmids in
E. cloacae complex.
Our study had several notable limitations. Our sample size was limited to available clinical CREC isolates at our hospital system and to published CREC genomes and may have reflected oversampling of clonal outbreaks. In order to perform Bayesian phylogenetic and phylogeographic analyses, several assumptions were required, and inherent limitations of these techniques may have introduced uncertainty into our findings. The accuracy of the evolutionary timeline for both ST171 and ST78 would be improved by the availability of more-recent clinical isolates or of additional earlier isolates collected prior to the early 2000s. Although we demonstrated high node support at all primary branch points in our analyses, the availability of additional isolates may lead to improved resolution of both recent branches with low support and long branches which could not be resolved due to a lack of earlier isolates. Moreover, our phylogeographic analysis was limited by the availability of isolates from only a few health care facilities and, more broadly, by the inclusion of isolates from only the Northeastern and northern Midwestern United States. Ultimately, phylogeographic analysis will produce a tree rooted in one of the sampled locations. Therefore, despite our high statistical support for the idea of an origin of ST171 in Boston, the future inclusion of isolates from additional locations may either support or refute this finding. Lastly, our cytotoxicity model was limited to demonstrating cytolytic activity of bacterial supernatant and may not fully reflect the in vivo virulence profile of CREC clones. In vivo models and functional studies are needed to further explore the role of specific genomic determinants in shaping the distribution and success of ST171 and ST78.
In summary, here we elucidated diverse evolutionary pathways of high-risk and sporadic E. cloacae clones in a large data set of genomes from across the United States and international sites. The inclusion of long-read sequencing and de novo hybrid assemblies, including new genomic and plasmid reference sequences, minimized reference bias and enabled detailed analysis of lineage-specific MGE and resistance gene repertoires. Our results indicate that, rather than heightened virulence, it was likely the proclivity of E. cloacae to acquire and disseminate multidrug resistance determinants, coupled with its ability to adapt to nosocomial environments, that led to the wide dissemination of CREC. The clonal expansion of ST171 across the United States and its subsequent local proliferation point to the need to pay increased attention to this high-risk clone. However, ongoing uptake of blaKPC-harboring plasmids has the potential to generate new CREC sublineages in ST78 and other E. cloacae complex subtypes. This indicates a need for heightened surveillance efforts attentive to the potential for both local and international spread of high-risk clones and the emergence of new CREC sublineages.